Neurocrine Biosciences
NBIX
NBIX
403 hedge funds and large institutions have $8.59B invested in Neurocrine Biosciences in 2020 Q4 according to their latest regulatory filings, with 63 funds opening new positions, 145 increasing their positions, 150 reducing their positions, and 73 closing their positions.
New
Increased
Maintained
Reduced
Closed
less capital invested
Capital invested by funds: $ → $
less ownership
Funds ownership: →
less repeat investments, than reductions
Existing positions increased: | Existing positions reduced:
less funds holding
Funds holding: →
14% less first-time investments, than exits
New positions opened: 63 | Existing positions closed: 73
29% less funds holding in top 10
Funds holding in top 10: 7 → 5 (-2)
66% less call options, than puts
Call options by funds: $39.8M | Put options by funds: $116M
Holders
403
Holding in Top 10
5
Calls
$39.8M
Puts
$116M
Top Buyers
| 1 | +$250M | |
| 2 | +$80.1M | |
| 3 | +$38.3M | |
| 4 |
PAMU
Pictet Asset Management (UK)
London,
United Kingdom
|
+$35.1M |
| 5 |
PA
Perceptive Advisors
New York
|
+$33.6M |
Top Sellers
| 1 | -$82.7M | |
| 2 | -$68.9M | |
| 3 | -$67.2M | |
| 4 |
Invesco
Atlanta,
Georgia
|
-$62.3M |
| 5 |
AllianceBernstein
Nashville,
Tennessee
|
-$61.3M |